High Growth Tech Stocks To Watch In The US July 2026
The United States market has remained flat over the past week but has experienced a significant 21% rise over the last year, with earnings projected to grow by 18% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability, positioning themselves well to capitalize on future opportunities in a dynamic economic environment.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| AppLovin | 21.14% | 21.74% | ★★★★★★ |
| Krystal Biotech | 29.70% | 36.60% | ★★★★★★ |
| 21.90% | 25.36% | ★★★★★★ | |
| Sandisk | 42.11% | 44.05% | ★★★★★★ |
| Palantir Technologies | 30.88% | 31.93% | ★★★★★★ |
| Zscaler | 14.32% | 55.01% | ★★★★★☆ |
| Tenaya Therapeutics | 59.68% | 60.87% | ★★★★★☆ |
| KVH Industries | 28.67% | 146.09% | ★★★★★☆ |
| Duos Technologies Group | 61.81% | 48.23% | ★★★★★☆ |
| Circle Internet Group | 20.74% | 47.65% | ★★★★★☆ |
Click here to see the full list of 61 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
SELLAS Life Sciences Group (SLS)
Simply Wall St Growth Rating: ★★★★★☆
Overview: SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company that develops novel therapeutics for various cancer indications in the United States, with a market cap of $2.63 billion.
Operations: SELLAS Life Sciences Group focuses on developing innovative cancer therapeutics in the U.S. The company operates as a late-stage clinical biopharmaceutical entity, with its market capitalization standing at $2.63 billion.
SELLAS Life Sciences Group, despite its current unprofitability, is poised for significant growth with an expected revenue increase of 66.3% annually, outpacing the US market's 12.9% growth rate. This biotech firm has recently filed a substantial $154.6 million Shelf Registration, indicating readiness for expansive financial maneuvers. Moreover, the company's presence in major industry conferences underscores its active engagement in the oncology sector and commitment to innovation—a crucial driver as it transitions towards profitability projected within three years at an impressive annual earnings growth rate of 64.2%. These developments suggest SELLAS is navigating its challenging phase with strategic initiatives that may set a robust foundation for future success.
Annexon (ANNX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for inflammatory-related diseases, with a market cap of $909.33 million.
Operations: Annexon, Inc. specializes in the discovery and development of treatments for inflammatory-related diseases but currently does not report any revenue segments.
Annexon, despite being unprofitable, shows promising growth with a forecasted annual revenue increase of 61%, significantly outpacing the US market average of 12.7%. Recent strategic index additions highlight its evolving market perception as a growth-oriented firm. At the Jefferies Global Healthcare Conference, CEO Douglas Love emphasized R&D innovations which are pivotal as Annexon aims for profitability within three years—a period expecting an impressive earnings growth rate of nearly 63%. These factors collectively underscore Annexon's transition from high potential to high impact in the tech sector.
- Unlock comprehensive insights into our analysis of Annexon stock in this health report.
Explore historical data to track Annexon's performance over time in our Past section.
AppLovin (APP)
Simply Wall St Growth Rating: ★★★★★★
Overview: AppLovin Corporation offers comprehensive AI-driven advertising solutions for businesses globally, with a market cap of $150.83 billion.
Operations: The company generates revenue primarily through its advertising segment, which reported $6.16 billion. The focus on AI-driven solutions positions it as a key player in the global advertising industry.
AppLovin's recent performance underscores its robust position in the tech landscape, with a notable 21.1% annual revenue growth outpacing the US market's 12.9%. At the forefront of innovation, its R&D expenses have been strategically increasing, reflecting in a significant earnings surge by 90.7% over the past year, well above its sector’s average growth of 14.4%. The firm also demonstrated confidence in its trajectory through substantial share repurchases totaling $5.6 billion since early 2022, underscoring a commitment to shareholder value amidst aggressive expansion efforts.
- Take a closer look at AppLovin's potential here in our health report.
Evaluate AppLovin's historical performance by accessing our past performance report.
Summing It All Up
- Discover the full array of 61 US High Growth Tech and AI Stocks right here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com